Kornimate/medical-research-clean huggingface dataset:
development of low cost devices to increase access to treadmill training

Conditions: Spinal Cord Injury

Summary: the goals of this model system program are to expand upon and advance the findings and outcomes of previous and current model systems clinical research, to continue to develop and study the effectiveness of innovative treatment strategies for persons with spinal cord injury (sci); and to evaluate the benefits of a well-designed, comprehensive, coordinated, interdisciplinary continuum of care that lead to improved outcomes for all persons with sci. in order to achieve these goals, the following objectives of the midwest regional spinal cord injury care system (mrscics) model system grant proposal will be accomplished.

the investigators will develop and assess the use of spring-loaded devices to assist limb swing and forward propulsion during body weight supported treadmill training (bwstt) (aim 1). prototype models of both devices have been developed. these devices will be: 1. simple to use in the clinical setting; 2. will be easily adjustable to alter the assistance provided; and, 3. will be able to quantify the amount of assistance necessary to facilitate normal stepping patterns. the investigators will also evaluate short- and long-term adaptations in locomotor performance following bwstt in individuals with incomplete sci with the use of these devices. this information will identify the effects of variable assistance at the limbs or trunk to modulate muscle activity and/or motor performance (kinematics) during stepping to maximize walking recovery.

Eligibility criteria:
inclusion criteria: * non-progressive lesion between spinal levels c1-t10 of \> 3 months duration. subjects with below t10 will be excluded due to potential lower motor neuron (lmn) injury * score \> 10 on the lower extremity motor score (lems) developed previously to measure strength in sci. for the lems criteria, preliminary data indicate that subjects with lems \< 10 in the chronic stages do not recover walking * all subjects must require physical assistance to ambulate on the treadmill at a speed of 4.0 kmph at 0% body weight support (bws) * all subjects will have an overground gait speed \<.8m/s * range of motion (ankle: -10 to 30 deg, knee: 0 to 90 deg, hip: -10 to 40 deg) consistent with gait * medically stable with medical clearance to participate (absence of concurrent illness, including unhealed decubiti, infection, cardiopulmonary disease, osteoporosis, active heterotrophic ossification or peripheral nerve damage in the lower limbs, history of traumatic head injury) * able to tolerate 30 minutes of upright (standing) position without orthostasis (decrease in blood pressure by 20 mmhg systolic and 10 mmhg diastolic; minimized with ambulatory population) * women of childbearing potential exclusion criteria: * women who are pregnant will be excluded due to potential forces at trunk from bws or pelvic assistance * those in concurrent physical therapy to eliminate effects of additional interventions
airway navigation database asia for diagnosis of peripheral pulmonary nodules

Conditions: Lung; Node

Summary: the study is designed to evaluate the efficacy and safety of augmented reality navigation system through intra-airway navigation system to guide bronchoscopy in the diagnosis of peripheral pulmonary nodules and explore the factors of diagnosis yield.

this is a single-arm, prospective, asian multicenter, real world case registry study. recruitment is expected to last up to 12 months, and each subject may be followed up for 12 months at most after surgery which depends on certain factors. the total duration of the study is about 24 months.the research is planned to be carried out at more than 10 sites.

Eligibility criteria:
inclusion criteria: 1. age ≥18; 2. chest thin-layer ct show that the peripheral pulmonary nodule (maximum diameter ≤3 cm) is not clearly diagnosed, and planned to be sampled and diagnosed by augmented reality navigation system guided bronchoscopy; 3. the target nodule is evaluated as being able to be reached via bronchoscope under the guidance of augmented reality navigation system before procedure; 4. patients can understand the study and sign informed consent form. exclusion criteria: - 1. contraindications for bronchoscopy: 1. myocardial infarction whithin 1 month. 2. active massive hemoptysis. 3. coagulation dysfunction. 4. pregnancy. 5. malignant arrhythmia, severe cardiac insufficiency, extreme systemic failure, etc. 2. severe cardiopulmonary dysfunction and other diseases that may significantly increase the risk of procedure; 3. the situations in which the investigators consider that patients are not suitable for this study.

Keywords: augmented reality navigation system peripheral pulmonary nodules biopsy
hand rehabilitation study for stroke patients

Conditions: Upper Extremity Paresis; Disability Physical; Chronic Stroke; Motor Disorders

Summary: the purpose of this study is to find out what are the best settings for applying electrical nerve stimulation over the skin for the short-term improvement of hand dysfunction after a stroke. the ultimate goal is to some day design an effective long-term training program to help someone recovery their ability to use their hands and function independently at home and in society. in order to know how to apply electrical nerve stimulation to produce a good long-term effect on hand dysfunction, the investigators first need to know how to make it work best in the short-term, and improve our understanding of for whom it works and how it works. the investigators will use a commercially available transcutaneous electrical nerve stimulation (tens) unit to gently apply electrical nerve stimulation over the skin of the affected arm. this is a portable, safe and easy to use device designed for patients to operate in their homes.


Eligibility criteria:
inclusion criteria: * age 18-80 years, has residual hand motor dysfunction caused by a single ischemic and/or hemorrhagic stroke greater than 6 months prior to enrollment. exclusion criteria: * pregnant; uncontrolled medical problems including but not limited to severe cardiovascular and cardiopulmonary disease; active cancer; significant hand joint deformity or other diagnosis with major effect on hand function besides stroke; severe alcohol or drug abuse within the past year; untreated or inadequately treated major depression; spasticity score \>3 on the mas; lack of finger range of motion of at least 10 degrees; severe aphasia or other communicative, behavioral or cognitive impairment that significantly interferes with the participant's ability to comply with the protocol or provide informed consent. in addition, patients will be excluded if they have a pacemaker.
intelligence and neurodevelopmental disorders after prenatal exposure to general anaesthesia

Conditions: General Anaesthesia During Pregnancy

Summary: every year in the european union, thousands of babies are exposed to anaesthesia before they are born because their mothers need surgery during pregnancy. while these surgeries are necessary, there is a concern that the anaesthesia might affect the baby's brain development. however, there isn't enough research to know for sure how this exposure might impact the child's intelligence or behavior later in life. the goal of this cohort study is to compare the intelligence and neurodevelopmental outcome of children prenatally exposed to general anaesthesia for maternal abdominal surgery with those of unexposed children.


Eligibility criteria:
prenatal anaesthesia exposure: inclusion criteria: * prenatal anaesthesia exposure: children exposed in utero to maternal general anaesthesia to allow laparoscopy or laparotomy for appendicectomy, adnexal pathology, cholecystectomy or for diagnostic procedures to rule out intra-abdominal pathology * no prenatal anaesthesia exposure: children not exposed to general anaesthesia for non-obstetric or obstetric (e.g. cesarean section) surgery in utero * children born in 2000-2023 * (parental) informed consent exclusion criteria: * children whose mothers underwent obstetric surgery or foetal surgery/interventions during the same pregnancy. * no dutch-speaking children * diagnosis of severe disability of genetic origin (e.g., fragil x, down syndrome,...), history of head trauma, major congenital birth defects

Keywords: anaesthesia anaesthesia-induced neurotoxicity pregnancy
very small embryonic-like stem cells for facial skin antiaging

Conditions: Stem Cell Transplant Complications; Skin Inflammation

Summary: the aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(vsels) to facial skin antiaging.

vsels come from the patient's peripheral blood, and will be injected in left preauricular area, followed by skin pathology to compare the improvement of skin aging. two 0.5 × 1 cm fragments of skin and subcutaneous tissue was removed from bilateral preauricular areas for morphologic analysis by optical and electron microscopy. histologic analysis of skin biopsy specimens was performed by hematoxylin and eosin, picrosirius red (for visualization of collagen), and orcein (for visualization of elastic fibers) staining.

Eligibility criteria:
inclusion criteria: • healthy volunteers with anti-aging willingness exclusion criteria: * metabolic and systemic diseases such as diabetes and atherosclerosis * facial skin diseases such as herpes, eczema, skin rash, systemic lupus erythematosus, dermatomyositis, connective tissue disease * endocrine disorders and cancer patients blood disease patients, thrombocytopenia or dysfunction, hypofibrinemia or anticoagulant therapy, long-term use of aspirin
prognostic value of carotid ceus in acute ischemic stroke patients

Conditions: Ultrasonography; Carotid Stenosis; Ischemic Stroke

Summary: contrast-enhanced ultrasound(ceus) of carotid artery plaque is a novel method that enabled direct visualization of neovessels in the vulnerable plaque. plaque enhancement with ceus showed correlation with the histologic density of neovessels within the carotid plaque and the previous cardiovascular events. vulnerable plaques with a high risk of thromboembolic complications and rapid progression is associated with acute ischemic stroke. the prognostic value of vulnerable carotid artery plaque depicted with ceus has not been fully investigated. the purpose of this study is to define prognostic value of plaque enhancement on carotid ceus in acute stroke patients. research question is; in acute ischemic stroke patients with ipsilateral carotid plaque as probable etiology of stroke, is the presence of carotid plaque enhancement on ceus independent predictor of future stroke.


Eligibility criteria:
inclusion criteria: 1. patients older than 19 years presenting acute ischemic stroke. 2. compatible neurologic symptom within 14 days 3. compatible mri finding (one or more positive dwi lesions in the territory of unilateral ica: aca or mca territory) - interpretable mri image obtained in snubh or outside hospital 4. etiology of acute ischemic stroke: except cardioembolic stroke (atrial fibrillation) and other determined etiology 5. ipsilateral extracranial carotid artery stenosis on mra (ce-mra), cta or doppler ultrasound exclusion criteria: 1. history of ipsilateral carotid stent or endarterectomy 2. carotid intervention during hospital stay 3. contraindication to ultrasound contrast agent (sonovue) a. right to left, bi-directional, or transient right to left cardiac shunts b. history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or any ultrasound contrast agent c. pregnant or lactating woman d. unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening congestive heart failure, or serious ventricular arrhythmias) 4. expected life span less than 12 months
prevention of recurrent aphthous stomatitis using vitamins

Conditions: Aphthous Stomatitis

Summary: the purpose of this research study is to find out if taking a multivitamin daily can affect the number of canker sores that people get and how long they last. previous studies have shown that people who get canker sores are more likely to be deficient in one or more vitamins. it has also been found that correction of such vitamin deficiencies reduces the number and duration of canker sores. however, it is not known if taking a multivitamin daily will reduce the number and duration of canker sores.


Eligibility criteria:
inclusion criteria: * patients willing and able to provide written informed consent for the study * patients with a history of at least three episodes of minor recurrent aphthous stomatitis (ras) within the past one year exclusion criteria: * patients with a history of other forms of ras (major, herpetiform) * patients who will be using any other vitamins/supplements during the study or those who have used any vitamins/supplements on a regular basis during the 90 days immediately preceding enrollment onto the study (regular use is defined as continuous daily use for at least a two week period) * patients who are under the age of 18 * women who are pregnant or nursing or those who plan to become pregnant * patients with a history of gout, kidney stones or iron overload disease * patients who currently smoke tobacco products * patients who are former smokers who have quit smoking within the past 30 days * patients with sulfite allergy * patients with a history of any systemic condition associated with oral ulceration. these include: behcet's syndrome, sweet's syndrome, celiac disease, crohn's disease, ulcerative colitis, hiv infection/aids, cyclic neutropenia and pfapa syndrome (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) * patients on medications commonly associated with causing oral ulceration. these include nicorandil, methotrexate and chemotherapeutic agents used for cancer. * patients using oral topical anti-inflammatory agents during the course of the study * patients who plan to use any products specifically for management of ras lesions * patients who are routinely using agents that could have an impact on duration of ras lesions (e.g., antibacterial mouthrinses) * patients receiving any other investigational agent during the course of ths study * patients with any other condition that might preclude participation in the study in the opinion of the study investigators

Keywords: aphthous stomatitis canker sores multivitamins vitamin deficiency
combining mri steatosis assessment and transient elastography to improve liver fibrosis diagnosis in non alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: the main objective is to compare the accuracy of transient elastography taking into account liver steatosis determined by mri, to liver biopsy for the diagnosis of liver fibrosis ≥f2 in patient with nafld.

no alcoholic fatty liver disease (nafld) is induced by an abnormal build up of fat in the liver. it can induce liver damage, namely fibrosis, which leads to cirrhosis and an increased risk of liver cancer. the diagnosis of liver fibrosis is thus critical to identify patients at risk. liver biopsy is the gold standard for the diagnosis of liver fibrosis. however this invasive test is expensive and has a significant morbidity. to avoid this others non invasive test have been developed to assess steatosis and fibrosis of the liver : * magnetic resonance imaging can quantify liver steatosis accurately. * transient elastography (fibroscan®) is approved for the diagnosis of fibrosis in chronic hepatitis c. however results in nafld were disappointing. further, steatosis by heightening liver elasticity is thought to be the cause of these poor results. * several biological tests or score are also approved in chronic hepatitis c, but not in nafld. the hypothesis driving this study is that by accounting for liver steatosis through the mean of mri, we could more accurately interpret transient elastography value to accurately diagnose the severity of liver fibrosis.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old * for which a liver biopsy is indicated for nafld according to current guidelines * presenting with at least one of the metabolic syndrome criteria: * bmi \> 25 kg/m² and/or waist circumference ≥ à 94cm for men / ≥ à 80cm for women * fasting glucose \> or = to 5,6 mmol/l or diabetes / or lowering glucose treatment * blood pressure ≥ 130/85 mmhg / or treatment * triglycerides ≥ than 1,7 mmol/l * hdl-c ≤ than 1 mmol/l (men), ≤ 1,3 mmol/l (women) /or lipid lowering treatment * affiliated to medical care insurance * having signed informed consent for participating in the study exclusion criteria: * associated other chronic liver disease : infectious, auto immune, genetic * alcohol consumption higher than 21 standard unit per week for men, or 14 standard unit for women; * steatosis inducing treatment: steroids, amiodarone, methotrexate, tamoxifen * history of bariatric surgery * contra indication to mri (pace maker, metallic foreign body, claustrophobia) * persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.

Keywords: nafld steatosis fibrosis transient elastography
treatment for stress and mixed urinary incontinence and vaginal vault prolapse

Conditions: Urinary Incontinence, Stress; Mixed Incontinence; Vaginal Vault Prolapse

Summary: the primary objective of this study is to further evaluate the safety and effectiveness of the use of a sling device in women for stress and mixed urinary incontinence as well as vaginal vault prolapse.

urinary incontinence is the involuntary loss of urine and can affect both men and women throughout their lives. women are more likely to develop incontinence as a result of pregnancy and childbirth. there are approximately 11 million cases of incontinence in the us contributing to several different types of incontinence including : * urge - 30% of the market * stress - 30% of the market of which 85% are women * combination urge and stress - 40% despite advances in behavioral therapy, pharmacological advances as well as development of minimally invasive surgical procedures, only one out of every twelve people affected actually seek help. prolapse globally, approximately 1 million women suffer uterovaginal prolapse annually and this condition can be associated with urinary incontinence. the breakdown of treatments for uterovaginal prolapse includes: * 20% - no treatment * 20% - non surgical management (pessary) * 60% - receive a surgical procedure of a suture repair or mesh repair there were greater than 600,000 surgeries performed globally to treat prolapse. these numbers are projected to increase due to rapid, easy, and less costly methods as well as new products that facilitate the easier procedures.

Eligibility criteria:
inclusion criteria: * subject must be female and \>18 years of age. * subject must have genuine stress or mixed incontinence and/or evidence of pelvic organ prolapse. exclusion criteria: * any subject with clotting defects, bleeding disorders or receiving anticoagulant treatments and is determined to be at risk for minimally invasive surgery as determined by the investigator * subjects who currently have an untreated urinary tract infection * subject is unable to comply with the study requirements, follow-up schedule, or to give valid informed consent. * subject is pregnant or desires future pregnancies.

Keywords: urge incontinence urinary incontinence vault prolapse stess incontinence mixed incontinence urine leakage enterocele rectocele cystocele
evaluation of the palmaz mach-5 grooved bare metal coronary stent system versus the palmaz bare metal coronary stent system in patients with symptomatic ischemic heart disease: a safety and performance study

Conditions: Ischemic Heart Disease

Summary: this is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the palmaz mach-5 grooved coronary stent system vs. the palmaz bare metal coronary stent system.


Eligibility criteria:
inclusion criteria: 1. male or female patients of any race greater than or equal to 18 years and of legal consent 2. patients must be willing to comply with the specified follow-up evaluation schedule 3. patients who sign an informed consent (signed and dated) prior to any study-related evaluation or procedure. 4. patients who are willing to undergo a follow-up coronary angiogram and endovascular imaging via optical coherence tomography 5. patients willing to be maintained on aspirin and clopidogrel bisulfate (plavix) for ninety (90) days post procedure. 6. patients with a de novo coronary lesion causing angina and/or a positive function test 7. patients who are eligible for percutaneous coronary interventions 8. low risk nstemi defined as patients with acs, unstable angina, positive cardiac biomarkers and hemodynamically stable as assessed by the investigator. 9. patients with an acceptable risk for coronary bypass graft surgery (cabg) intra-procedure angiographic criteria: 1. single de novo target lesion \>50% diameter stenosis by angiography 2. single target vessel 2.75 to 3.25 mm diameter 3. lesion length of 14 to 20mm which is suitable for palmaz mach-5 grooved coronary stent system or the palmaz bare metal coronary stent system. exclusion criteria: 1. known allergy or sensitivity to cobalt chromium (cocr) alloy or its components. 2. known sensitivity or allergy to aspirin, radiographic contract agents (that cannot be pre-treated adequately). 3. patients unable to tolerate anticoagulant therapy or antiplatelet therapy. 4. history of bleeding or known coagulopathy. 5. patients with thrombocytopenia and or neutropenia. 6. more than one stenosis \>50% in target vessel. 7. lesion in aortic ostium. 8. left main or lad, cx lesions within 2-mm from the origin. 9. ejection fraction \<45%. 10. stemi in evolution. 11. disabling stroke within previous 30 days. 12. patients currently enrolled in another investigational device or drug study. 13. previous enrollment in this study. 14. women who are currently pregnant. (a negative pregnancy test for female subjects of child bearing potential is required within 24 hours of procedure.) 15. known or suspected active systemic infection. 16. evidence of severe or uncontrolled systemic diseases, including chronic renal insufficiency, or any condition which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.